Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk

Transplant International

Volumn 23, Issue 12, 2010, Pages 1191-1204

  Liefeldt, Lutz ^a   Budde, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

cardiovascular risk factors; diabetes mellitus; graft survival; immunosuppressants; renal transplantation

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID;

AGE DISTRIBUTION; ANEMIA; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE EXACERBATION; DYSLIPIDEMIA; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART DEATH; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; METABOLIC SYNDROME X; OBESITY; ORGAN TRANSPLANTATION; PATIENT CARE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK ASSESSMENT; SMOKING;

ANEMIA; CARDIOVASCULAR DISEASES; CREATININE; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; RISK FACTORS;

EID: 78649261874     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01159.x     Document Type: Review

References (123)

1. Foley RN, Parfrey PS, Sarnak MJ,. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112.
2. Baigent C, Burbury K, Wheeler D,. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147.
3. Sarnak MJ, Levey AS,. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35: S117.
4. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B,. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 2004; 4: 1662.
5. Shirali AC, Bia MJ,. Management of cardiovascular disease in renal transplant recipients. Clin J Am Soc Nephrol 2008; 3: 491.
6. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl. 3): S1.
7. Lentine KL, Rocca Rey LA, Kolli S, et al. Variations in the risk for cerebrovascular events after kidney transplant compared with experience on the waiting list and after graft failure. Clin J Am Soc Nephrol 2008; 3: 1090.
8. Abedini S, Holme I, Fellström B, et al. Cerebrovascular events in renal transplant recipients. Transplantation 2009; 87: 112.
9. Snyder JJ, Kasiske BL, Maclean R,. Peripheral arterial disease and renal transplantation. J Am Soc Nephrol 2006; 17: 2056.
10. Muntner P, He J, Hamm L, Loria C, Whelton PK,. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13: 745.
11. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int 2002; 62: 1402.
12. Abbott KC, Yuan CM, Taylor AJ, Cruess DF, Agodoa LY,. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003; 14: 2358.
13. Meier-Kriesche HU, Baliga R, Kaplan B,. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75: 1291.
14. Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5: 1986.
15. Sechi LA, Catena C, Zingaro L, Melis A, De Marchi S,. Abnormalities of glucose metabolism in patients with early renal failure. Diabetes 2002; 51: 1226.
16. Natali A, Pucci G, Boldrini B, Schillaci G,. Metabolic syndrome: at the crossroads of cardiorenal risk. J Nephrol 2009; 22: 29.
17. Wanner C, Ritz E,. Reducing lipids for CV protection in CKD patients-current evidence. Kidney Int Suppl 2008; 4: S24.
18. Vanrenterghem Y, Ponticelli C, Morales JM, et al. Prevalence and management of anemia in renal transplant recipients: a European survey. Am J Transplant 2003; 3: 835.
19. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP,. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311.
20. Opelz G, Dohler B,. Influence of time of rejection on long-term graft survival in renal transplantation. Transplantation 2008; 85: 661.
21. Kasiske BL, Chakkera HA, Roel J,. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735.
22. Soveri I, Holdaas H, Jardine A, Gimpelewicz C, Staffler B, Fellstrom B,. Renal transplant dysfunction - importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006; 21: 2282.
23. Lentine KL, Brennan DC, Schnitzler MA,. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 2005; 16: 496.
24. Miles AM, Sumrani N, Horowitz R, et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998; 65: 380.
25. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43: 1071.
26. Opelz G, Dohler B,. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5: 2725.
27. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation - a pilot study. Transplantation 1996; 61: 1469.
28. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5: 2929.
29. Kobashigawa JA, Kasiske BL,. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331.
30. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL,. Chronic renal allograft rejection: immunologic and nonimmunologic risk factors. Kidney Int 1996; 49: 518.
31. Roodnat JI, Mulder PG, Zietse R, et al. Cholesterol as an independent predictor of outcome after renal transplantation. Transplantation 2000; 69: 1704.
32. Winkelmayer WC, Chandraker A,. Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol 2008; 3 (Suppl. 2): S49.
33. Levin A, Singer J, Thompson CR, Ross H, Lewis M,. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347.
34. Kamar N, Rostaing L,. Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 2008; 85: 1120.
35. Khanna A, Plummer M, Bromberek C, Bresnahan B, Hariharan S,. Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. Kidney Int 2002; 62: 2257.
36. Ojo AO,. Renal disease in recipients of nonrenal solid organ transplantation. Semin Nephrol 2007; 27: 498.
37. Solez K, Vincenti F, Filo RS,. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736.
38. Artz MA, Boots JM, Ligtenberg G, et al. Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 2003; 14: 1880.
39. Bolin P Jr, Shihab FS, Mulloy L, et al. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results. Transplantation 2008; 86: 88.
40. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC,. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005; 4: CD003961.
41. Silva HT Jr, Yang HC, Abouljoud M, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595.
42. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7: 1506.
43. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
44. Grinyo JM, Ekberg H, Mamelok RD, et al. The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. Nephrol Dial Transplant 2009; 24: 2269.
45. Boots JM, Christiaans MH, Van Hooff JP,. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64: 2047.
46. Delgado P, Diaz JM, Silva I, et al. Unmasking glucose metabolism alterations in stable renal transplant recipients: a multicenter study. Clin J Am Soc Nephrol 2008; 3: 808.
47. Hjelmesaeth J, Hartmann A, Kofstad J, et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979.
48. Andrews RC, Walker BR,. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci (Lond) 1999; 96: 513.
49. Gallon LG, Winoto J, Leventhal JR, Parker MA, Kaufman DB,. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006; 1: 1029.
50. Boots JM, Van Duijnhoven EM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP,. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221.
51. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J,. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
52. Woodle ES,. A prospective, randomized, multicenter, double-blind study of early corticosteroid cessation versus long-term maintenance of corticosteroid therapy with tacrolimus and mycophenolate mofetil in primary renal transplant recipients: one year report. Transplant Proc 2005; 37: 804.
53. Van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, Van Hooff JP,. Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 2002; 13: 213.
54. Fellstrom B,. Risk factors for and management of post-transplantation cardiovascular disease. BioDrugs 2001; 15: 261.
55. Johnston O, Rose CL, Webster AC, Gill JS,. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411.
56. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 2008; 57: 945.
57. Kim JH, Kim JE, Liu HY, Cao W, Chen J,. Regulation of interleukin-6-induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem 2008; 283: 708.
58. Araki M, Fahmy N, Zhou L, et al. Expression of IL-8 during reperfusion of renal allografts is dependent on ischemic time. Transplantation 2006; 81: 783.
59. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883.
60. Kasiske BL, Vazquez MA, Harmon WE, et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 11 (Suppl. 15): S1.
61. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J,. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775.
62. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48: 37.
63. Raine AE, Carter R, Mann JI, Morris PJ,. Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. Nephrol Dial Transplant 1988; 3: 458.
64. Derfler K, Hayde M, Heinz G, et al. Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin A. Kidney Int 1991; 40: 720.
65. Kasiske BL, De Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8: 1384.
66. Morrisett JD, Abdel-Fattah G, Kahan BD,. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003; 35: 143S.
67. Augustine JJ, Knauss TC, Schulak JA, Bodziak KA, Siegel C, Hricik DE,. Comparative effects of sirolimus and mycophenolate mofetil on erythropoiesis in kidney transplant patients. Am J Transplant 2004; 4: 2001.
68. De Fijter JW, Mallat MJ, Doxiadis II, et al. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001; 12: 1538.
69. Halimi JM, Laouad I, Buchler M, et al. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 2005; 5: 2281.
70. Halimi JM, Matthias B, Al Najjar A, et al. Respective predictive role of urinary albumin excretion and nonalbumin proteinuria on graft loss and death in renal transplant recipients. Am J Transplant 2007; 7: 2775.
71. Halimi J, Laouad I, Buchler M, et al. Early proteinuria is a strong indicator of donor renal lesions, ischemia-reperfusion injury and immunological aggression. Transplant Proc 2006; 38: 2319.
72. Prasad GV, Bandukwala F, Huang M, Zaltzman JS,. Microalbuminuria post-renal transplantation: relation to cardiovascular risk factors and C-reactive protein. Clin Transplant 2009; 23: 313.
73. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17: 889.
74. Opelz G, Zeier M, Laux G, Morath C, Dohler B,. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17: 3257.
75. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA,. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007; 7: 2350.
76. Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010; 25: 967.
77. Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006; 82: 368.
78. Letavernier E, Legendre C,. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 2008; 22: 125.
79. Ozdemir FN, Karakan S, Akgul A, Haberal M,. Metabolic syndrome is related to long-term graft function in renal transplant recipients. Transplant Proc 2009; 41: 2808.
80. Courivaud C, Kazory A, Simula-Faivre D, Chalopin JM, Ducloux D,. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation 2007; 83: 1577.
81. Ducloux D, Kazory A, Simula-Faivre D, Chalopin JM,. One-year post-transplant weight gain is a risk factor for graft loss. Am J Transplant 2005; 5: 2922.
82. Lentine KL, Rocca-Rey LA, Bacchi G, et al. Obesity and cardiac risk after kidney transplantation: experience at one center and comprehensive literature review. Transplantation 2008; 86: 303.
83. DeLoach SS, Joffe MM, Mai X, Goral S, Rosas SE,. Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. Nephrol Dial Transplant 2009; 24: 1314.
84. Mazzaferro S, Pasquali M, Taggi F, et al. Progression of coronary artery calcification in renal transplantation and the role of secondary hyperparathyroidism and inflammation. Clin J Am Soc Nephrol 2009; 4: 685.
85. Abedini S, Holme I, Marz W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4: 1246.
86. Bandukwala F, Huang M, Zaltzman JS, Nash MM, Prasad GV,. Association of uric acid with inflammation, progressive renal allograft dysfunction and post-transplant cardiovascular risk. Am J Cardiol 2009; 103: 867.
87. Ducloux D, Deschamps M, Yannaraki M, et al. Relevance of Toll-like receptor-4 polymorphisms in renal transplantation. Kidney Int 2005; 67: 2454.
88. Wong BM, Huang M, Zaltzman JS, Prasad GV,. Mycophenolate mofetil and C-reactive protein in renal transplant recipients. Transplantation 2007; 83: 48.
89. Yilmaz MI, Qureshi AR, Carrero JJ, et al. Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease. Am J Nephrol 2010; 31: 214.
90. Yilmaz MI, Saglam M, Carrero JJ, et al. Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT A novel marker of endothelial damage? Clin Transplant 2009; 23: 241.
91. Abedini S, Meinitzer A, Holme I, et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients. Kidney Int 2010; 77: 44.
92. Israni AK, Snyder JJ, Skeans MA, et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant 2010; 10: 338.
93. Paoletti E, Cannella G,. Reducing the risk of left ventricular hypertrophy in kidney transplant recipients: the potential role of mammalian target of rapamycin. Transplant Proc 2009; 41: S3.
94. Parfrey PS, Harnett JD, Foley RN, et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation 1995; 60: 908.
95. Middleton RJ, Parfrey PS, Foley RN,. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol 2001; 12: 1079.
96. Paoletti E, Amidone M, Cassottana P, Gherzi M, Marsano L, Cannella G,. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year nonrandomized controlled trial. Am J Kidney Dis 2008; 52: 324.
97. Gallagher M, Jardine M, Perkovic V, et al. Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation 2009; 87: 1877.
98. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 559.
99. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
100. Abramowicz D, Del Carmen RM, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234.
101. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007; 7: 560.
102. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79: 466.
103. Suwelack B, Gerhardt U, Hohage H,. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
104. Abramowicz D, Hadaya K, Hazzan M, et al. Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. Nephrol Dial Transplant 2008; 23: 3727.
105. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
106. Luan FL, Steffick DE, Gadegbeku C, Norman SP, Wolfe R, Ojo AO,. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant 2009; 9: 160.
107. Srinivas TR, Meier-Kriesche HU,. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol 2008; 3 (Suppl. 2): S101.
108. Meier-Kriesche HU, Schold JD, Kaplan B,. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289.
109. Matas AJ, Kandaswamy R, Gillingham KJ, et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005; 5: 2473.
110. Pascual J, Zamora J, Galeano C, Royuela A, Quereda C,. Steroid avoidance or withdrawal for kidney transplant recipients. Cochrane Database Syst Rev 2009; 11: CD005632.
111. Ghisdal L, Bouchta NB, Broeders N, et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature. Transpl Int 2008; 21: 146.
112. Grotz W, Siebig S, Olschewski M, Strey CW, Peter K,. Low-dose aspirin therapy is associated with improved allograft function and prolonged allograft survival after kidney transplantation. Transplantation 2004; 77: 1848.
113. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1.
114. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 336: 645.
115. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361: 2024.
116. Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering in chronic stable renal transplant recipients: the FAVORIT trial. Presented at: the American Society of Nephrology Renal Week 2009; October 27-November 1; San Diego, CA. Abstract LB-001.
117. Carpenter MA, Bostom A, Kusek J, et al. Untreated CVD risk factors in chronic, stable kidney transplant recipients at baseline in the folic acid for vascular outcome reduction (FAVORIT) study. Presented at: the American Society of Nephrology Renal Week 2009; October 27-November 1; San Diego, CA. Abstract PUB271.
118. Sharif A, Moore R, Baboolal K,. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; 85: 353.
119. Patel RK, Mark PB, Johnston N, et al. Prognostic value of cardiovascular screening in potential renal transplant recipients: a single-center prospective observational study. Am J Transplant 2008; 8: 1673.
120. Segoloni GP, Quaglia M, Giacosa C, Ferro M, Martina G, Piccoli GB,. Renal transplantation from cadaveric donor after myocardial revascularization: still a matter of concern? Transplant Proc 2004; 36: 2635.
121. Claes K, Bammens B, Evenepoel P, et al. Troponin I is a predictor of acute cardiac events in the immediate postoperative renal transplant period. Transplantation 2010; 89: 341.
122. Hickson LT, El Zoghby ZM, Lorenz EC, Stegall MD, Jaffe AS, Cosio FG,. Patient survival after kidney transplantation: relationship to pretransplant cardiac troponin T levels. Am J Transplant 2009; 9: 1354.
123. Lentine KL, Hurst FP, Jindal RM, et al. Cardiovascular risk assessment among potential kidney transplant candidates: approaches and controversies. Am J Kidney Dis 2010; 55: 152.